Advertisement
U.S. markets closed

BioSenic S.A. (BIOS.BR)

Brussels - Brussels Delayed Price. Currency in EUR
0.0320+0.0018 (+5.96%)
At close: 04:44PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0302
Open0.0314
BidN/A x N/A
AskN/A x N/A
Day's Range0.0300 - 0.0322
52 Week Range0.0230 - 0.2095
Volume577,102
Avg. Volume1,097,986
Market Cap6.041M
Beta (5Y Monthly)N/A
PE Ratio (TTM)0.00
EPS (TTM)7.5300
Earnings DateMar 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BIOS.BR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      BioSenic raises €500,000 in private placement of new shares with established new investors

      PRESS RELEASE – REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Mont-Saint-Guibert, Belgium, 2 February 2024, 17:30 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it ra

    • GlobeNewswire

      BioSenic provides support to forthcoming European conference on graft-versus-host disease

      Mont-Saint-Guibert, Belgium, January 31, 2024, 7.00 am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it will attend and support the upcoming GvHGvL Meeting on 13-15 March, 2024 at University Hospital Regensburg, a biannual conference to lead scientific exchange around graft-versus-host disease (GvHD). GvHD can result from transplanting bone marrow or stem cells fr

    • GlobeNewswire

      BioSenic patent granted in Canada for broader protection of ATO therapeutic platform

      PRESS RELEASE – INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration.Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery, which has demonstrated increased therapeutic potential for indications ranging from immune to cancer and infectious diseases. Mont-Saint-Guibert, Belgium